Performance of the GenoType MTBDRsl V 2.0 for detecting second-line drugs resistance of Mycobacterium tuberculosis isolates in Tunisia
| Autor: | Imen Bouzouita, Andrea M. Cabibbe, Henda Draoui, Leila Essalah, Sana Bejaoui, Alberto Trovato, Férièle Messadi, Daniela Maria Cirillo, Leila Slim-Saidi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Tunisia Adolescent Genotype Capreomycin Microbial Sensitivity Tests Biology Microbiology Rapid detection Mycobacterium tuberculosis Young Adult 03 medical and health sciences Second line Drug Resistance Multiple Bacterial Tuberculosis Multidrug-Resistant medicine Humans Antibiotics Antitubercular Molecular Biology Aged 030304 developmental biology Aged 80 and over 0303 health sciences Whole Genome Sequencing 030306 microbiology Kanamycin General Medicine Drug susceptibility Middle Aged biology.organism_classification Virology Molecular Diagnostic Techniques Amikacin Female Reagent Kits Diagnostic Rifampin medicine.drug |
| Zdroj: | Research in Microbiology. 172:103816 |
| ISSN: | 0923-2508 |
| DOI: | 10.1016/j.resmic.2021.103816 |
| Popis: | Rapid detection of the second-line drug (SLD) resistant tuberculosis (TB) strains is challenging to prescribe an immediate adequate treatment and limit the transmission of SLD resistant strains. The study aimed to evaluate the performance of GenoType MTBDRsl V2.0 compared to phenotypic drug susceptibility testing (pDST:MGIT960) to detect resistance to SLD of Mycobacterium tuberculosis (MTB) isolates in Tunisia, between May 2015 and December 2019. As a matter of fact, 103 rifampicin-resistant and multidrug-resistant MTB strains were included. Discrepancies between pDST and MTBDRsl were solved by whole genome sequencing . Compared to pDST, MTBDRsl V2.0 showed a sensitivity of 92.8% (68.5%–98.7%) in detecting resistance to fluoroquinolones. As for second-line injectable drugs, it presented a sensitivity of 80.0% (49.0%–94.3%). MTBDRsl had sensitivities of 100.0% (67.5%–100.0%), 75.0% (40.9%–92.8%) and 100.0% (60.9%–100.0%) respectively for kanamycin, capreomycin and amikacin. The specificity was 100.0% for all the drugs evaluated. As for diagnosing XDR-TB, it had a sensitivity of 57.1% (25.0%–84.1%) and a specificity of 100.0% (96.1%–100.0%). MTBDRsl V2.0 showed a high performance in detecting SLD resistance with a short turnaround time compared with pDST, which made it possible to start an early treatment and to maintain a low prevalence of SLD resistance and XDR-TB in Tunisia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect